Skip to main content
Caplight Logo









Montai Health

Montai Health

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.montai.com/

Last Round

Series A

Dec 13, 2022

Total Funding Raised

$50M

Company Overview

Montai Health is a biotechnology company that uses artificial intelligence and its proprietary CONECTA platform to discover and develop small-molecule oral medicines for chronic inflammatory and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoveryAI drug discoverysmall-molecule therapeuticsbiotechnologyin silico drug discoverybioactive compoundschronic disease treatmentcomputational biologypharmaceutical R&Ddigital compound libraryAI-native biotechdrug discovery platformdata as a serviceDaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Montai Health Comparables

Compare Montai Health with similar companies based on industry and business-model similarity.

Montai Health comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Terray Therapeutics
83%
Cellarity
82%
Genesis Molecular AI
81%

Montai Health Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 13, 2022

Key People

Founding team and executive leadership

Hok Hei Tam

CTO

Executive Team

Hans Hull

Chief Operating Officer

Executive Team

Kyle Chiang

COO

Executive Team

Montai Health Investors

Notable investors and investment history

Montai Health investors
InvestorRounds
Flagship PioneeringSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 13, 2025

    Preclinical data presented for novel oral NRF2 agonist MTAI-1025 for ulcerative colitis.

  • Oct 28, 2025

    Hans Hull appointed as the new Chief Operations Officer.

Montai Health Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Montai Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Montai Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range62
Year Founded2019
Last FundingDec 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?